Back to Search
Start Over
UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib.
- Source :
-
Data in brief [Data Brief] 2022 Feb 23; Vol. 41, pp. 107991. Date of Electronic Publication: 2022 Feb 23 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Imatinib is a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia. It enters the environment by excretion from the body through urine and feces and is transferred with wastewater to a wastewater treatment plant. There, it can be degraded by activated sludge, forming a number of biotransformation products. Presence of imatinib and its potential transformation products in the environment can impose a high risk to aquatic organisms and human health, therefore it is important to obtain knowledge of its environmental fate. The data presented here is a result of a simulated biodegradation of imatinib at two levels of activated sludge using a batch biotransformation setup, with and without carbon source. The data was acquired with UHPLC-HRMS/MS and processed by MzMine2.36 [1]. The dataset presents a table of [M+H] <superscript>+</superscript> features with retention times and corresponding MS/MS data. With development of new data mining tools this data can be used to identify new transformation products of imatinib and with it fully understand its environmental fate and the risk associated with its presence in the environment.<br />Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (© 2022 The Author(s). Published by Elsevier Inc.)
Details
- Language :
- English
- ISSN :
- 2352-3409
- Volume :
- 41
- Database :
- MEDLINE
- Journal :
- Data in brief
- Publication Type :
- Academic Journal
- Accession number :
- 35257019
- Full Text :
- https://doi.org/10.1016/j.dib.2022.107991